Tumor Ablation Market worth $580.1 Million by 2021

By -

North America is expected to account for the largest share of the market during the forecast period

(EMAILWIRE.COM, September 01, 2021 ) The tumor ablation market is projected to grow from an estimated USD 321.9 Million in 2016 to USD 580.1 million by 2021 at a CAGR of 12.5%.

Growth in the tumor ablation market is mainly driven by the significant geriatric population and rising cancer patient population across the globe, and ongoing technological advancements in the field of tumor ablation products.

By technology, the microwave ablation segment is expected to grow at the highest rate during the forecast period in the tumor ablation market

The microwave tumor ablation technology is the fastest-growing ablation technology segment that is currently being used to treat various cancers (such as liver, lung, and kidney).

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142550258

Growth in the in microwave ablation segment is attributed to increasing private funding for novel product development of microwave ablation, its significant efficiency over other ablation technologies, and growing adoption of the microwave tumor ablation procedure among healthcare professionals to treat various cancers.

By mode of treatment, surgical ablation segment is expected to be the largest contributor to the tumor ablation market in 2016

Surgical tumor ablation is a minimally invasive surgical procedure in which ablation probes/catheters are used to deliver energy directly to the cancer site for treatment. This does not involve surgical removal of affected tissues or tumors. Surgical ablation is performed on patients ineligible for the surgical removal of tumor/cancer tissue.

The stable market growth witnessed by the surgical tumor ablation segment is mainly due to the large number of minimally invasive surgical procedures performed in mature markets (such as the U.S., the U.K., Italy, Germany, and Japan) to treat various cancers, growing market awareness about the benefits of surgical ablation in emerging markets (coupled with rapid modernization of regional healthcare infrastructure), and large proportion of cancer patients ineligible for surgical cancer treatment (paired with growing patient base for key cancers such as liver, kidney, lung, and prostate).

North America is expected to account for the largest share of the market during the forecast period

North America is one of the major revenue-generating regions in the global tumor ablation market. The large share of this regional segment can mainly be attributed to early introduction of tumor ablation technologies in the region, continuous technological advancements occurring in the field of tumor ablation catheters, and growing private-public investments to develop innovative tumor ablation technologies (coupled with the growing public awareness related to the benefits of tumor ablation).

Key Market Players

The tumor ablation market is a diverse and highly competitive market with a large number of players. Some of the prominent players in the tumor ablation are Medtronic, Plc (U.S.), AngioDynamics, Inc. (U.S.), HealthTronics, Inc. (U.S.), Galil Medical, Inc. (U.S.) and Boston Scientific Corporation (U.S.).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=142550258

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Media Contact

Related Tags

Read other news from MarketsandMarkets™

Timing Devices Market Size, Share, Revenue Trends & Forecast to 2030

MarketsandMarkets™ - Sep 18, 2023
Timing Devices Market by Type (Oscillators, Atomic Clocks, Clock Generators, Clock Buffers, Jitter Attenuators), Material (Crystal, Silicon, Ceramic), Vertical (Consumer Electronics, Automotive) and Region - Global Forecast to 2030 ...Read more

Artificial Intelligence Market Segmented by Product, Top Manufacturers, Geography Trends & Growth Opportunity to 2030

MarketsandMarkets™ - Sep 18, 2023
Artificial Intelligence technology such as machine learning, natural language processing, computer vision, and others are revolutionizing various sectors, including healthcare, finance, manufacturing, and retail. ...Read more

Digital PCR (dPCR) and Real-time PCR (qPCR) Market worth $12.4 billion by 2028, at a CAGR of 7.8%.

MarketsandMarkets™ - Sep 18, 2023
"Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospital, Diagnostic Labs, Pharma, Biotech, CROs) - Global Forecast to 2028". ...Read more